2022 Chinese guideline for the management of pregnancy and reproduction in patients with systemic lupus erythematous

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects women of childbearing age. With the improvement of diagnosis and treatment, the survival rate of SLE patients has improved significantly, but pregnancy is still an important challenge for SLE patients. It is urgent to strengthen the reproductive and pregnancy management of SLE patients and standardize the peri-gestational monitoring and treatment of SLE patients. This guideline is jointly sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR), and Chinese Research Committee of pregnancy and reproduction in autoimmune rheumatic diseases (CHOPARD). Guided by clinical problems, after several rounds of clinical and methodological expert demonstration and selection, 13 clinical problems that need to be solved are finally formed, based on evidence-based medical evidence and expert opinions, guideline recommendations are given. The aim is to improve the pregnancy success rate and reduce the maternal and infant mortality rate in SLE patients.

系统性红斑狼疮（SLE）是一种好发于育龄期女性的自身免疫病。随着诊治水平的提高，SLE患者的存活率已显著升高，但妊娠仍是SLE患者面临的重要挑战之一。加强SLE患者生殖与妊娠管理、规范SLE患者围妊娠期监测与治疗已迫在眉睫。本指南由国家皮肤与免疫疾病临床医学研究中心、国家妇产疾病临床医学研究中心、中国系统性红斑狼疮研究协作组、中国风湿免疫病相关生殖及妊娠研究委员会联合发起，以临床问题为导向，经过多轮临床、方法学专家论证及遴选，最终形成13条亟待解决的临床问题，结合循证医学证据及专家意见给出指南推荐意见，旨在提高SLE患者妊娠成功率，降低母婴病死率。.